Artificial intelligence can help clinical trial teams analyze complex evidence, identify eligible patients, forecast operational risk, monitor data, and prioritize expert attention. Its value depends on fit with the protocol and workflow, representative data, validation, traceability, privacy, and meaningful human oversight.
AI should not be treated as one technology or one decision. Each application has a different user, consequence, evidence requirement, and regulatory context.
Practical AI use cases in clinical trials
Protocol and feasibility analysis
Natural language processing can structure inclusion criteria, compare protocol complexity, and analyze historical feasibility. Predictive models can help estimate enrollment and site performance, but teams must account for changes in indication, geography, competition, and protocol design.
Patient identification and matching
Systems can convert eligibility criteria into computable logic and search approved clinical data for potential candidates. Useful implementations show why a patient may match and keep qualified clinicians responsible for review.
Site selection and enrollment forecasting
Models may combine historical performance, patient population, startup time, investigator experience, and operational context. Avoid perpetuating historical allocation patterns without testing fairness and generalization.
Risk-based monitoring
Analytics can prioritize sites, participants, or data points for review using anomalies, protocol deviations, timeliness, and quality signals. The output should direct attention—not hide the underlying evidence.
Clinical data review
AI can identify inconsistent values, unusual patterns, missing information, and possible safety signals. Integration with existing review and query workflows is essential.
Document and knowledge workflows
Generative AI can summarize approved documents, compare versions, extract structured facts, and help experts navigate procedures. Ground responses in authoritative content and preserve citations.
The clinical trial data foundation
Relevant data may span electronic data capture, clinical trial management, electronic health records, laboratories, imaging, wearables, safety systems, documents, and external real-world sources.
Before modeling, establish:
- common participant, site, study, and event identifiers;
- documented provenance and transformation lineage;
- time alignment and version history;
- quality checks tied to critical data;
- role-based access and privacy controls; and
- clear ownership of derived variables and labels.
Poor interoperability can create more risk than an imperfect algorithm.
Validation and monitoring
Validation must reflect intended use. Define the population, user, input data, output, action, and consequence of error. Evaluate performance across relevant sites, populations, time periods, devices, and operating conditions.
For generative systems, assess factual support, citation correctness, completeness, consistency, and refusal behavior. For predictive models, examine calibration, sensitivity, specificity, lead time, and subgroup performance as appropriate.
After deployment, monitor input changes, missingness, output distributions, user overrides, downstream outcomes, and incidents. Changes to data pipelines or study procedures can affect performance even when model code is unchanged.
Governance questions to answer
- Is the system making a recommendation, prioritizing review, or executing an action?
- What evidence can the user inspect?
- Who may access participant-level data and model output?
- How are validation, versions, and changes documented?
- When must a person intervene or override the system?
- What happens when required data is unavailable?
- Who owns monitoring and incident response?
Governance should be proportionate to intended use and developed with quality, clinical, privacy, security, and regulatory stakeholders.
Measuring value
Measure operational outcomes such as enrollment time, screen-failure reduction, review workload, query cycle time, protocol deviation detection, and monitoring efficiency. Pair efficiency metrics with quality and safety measures to avoid optimizing speed at their expense.
A successful pilot should demonstrate both technical performance and a credible path to integration, validation, adoption, and operation.
Frequently asked questions
Can AI select participants for a clinical trial?
AI can identify and rank potential matches, but intended use, data limitations, privacy, validation, and clinical responsibility must be defined. Human review is generally important for consequential eligibility decisions.
Can generative AI be used with clinical documents?
Yes, for bounded use cases with approved sources, permission controls, citations, evaluation, and review. Sensitive data handling and provider terms must be assessed explicitly.
What is the best first clinical AI use case?
A good first use case has accessible representative data, a measurable operational bottleneck, knowledgeable users, manageable risk, and an integration path. Document navigation or expert prioritization may be more suitable than autonomous decisions.
Develop clinical AI around evidence
ReactMotion.ai helps pharmaceutical teams integrate research and clinical data and build evaluated AI applications for trial operations and knowledge workflows. Explore pharmaceutical AI solutions or schedule a consultation.
